PERSEPHONE: Duration of trastuzumab with chemotherapy in women with HER2-positive early breast cancer—Six versus twelve months.
Helena Margaret Earl
No relevant relationships to disclose
David A. Cameron
No relevant relationships to disclose
David Miles
No relevant relationships to disclose
Andrew M. Wardley
No relevant relationships to disclose
Emma Ogburn
No relevant relationships to disclose
A-L Vallier
No relevant relationships to disclose
Shrushma Loi
No relevant relationships to disclose
Helen B Higgins
No relevant relationships to disclose
Louise Hiller
No relevant relationships to disclose
Janet A. Dunn
No relevant relationships to disclose